VALENTI, LUCA VITTORIO CARLO
VALENTI, LUCA VITTORIO CARLO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
IFNAR2 p.F8S Variant Associates with Severe COVID-19 and Adaptive Immune Cell Activation Modulation
2026 F. Malvestiti, A. Lombardi, F. Gentile, V. Torcianti, E. Trombetta, A. Cherubini, G. Lamorte, S.C.U. Renteria, D. Marchelli, L. Rosso, A. Bandera, F. Peyvandi, F. Blasi, G. Grasselli, L. Porretti, S. Alqahtani, D. Prati, R. Gualtierotti, B. Soskic, V. Vaira, L. Ronzoni, L. Valenti
Burden of metabolic diseases, 1990-2023, with forecasts to 2030 for the Asia-Pacific region
2026 H. Zhang, Q. Chen, G. Lip, H. Tilg, L. Valenti, V. Somers, C. Byrne, G. Targher, W. Yang, C. Mantzoros, A. Misra, A. Lonardo, K. Alswat, K. Sung, M. Muthiah, X. Zhou, M. Zheng
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis: Therapeutic Options and Approaches to Treatment
2026 M. Tincopa, E. Speliotes, L. Valenti, R. Loomba
Hepatic GPR110 contributes to sex disparity in the development of MASH through oestrogen receptor α-dependent signalling
2026 F. Yang, W. Wang, F. Qiu, R. Qing, Q. Gao, X. Yan, D. Wu, H. Hui, R. Dang, G. Jiang, L. Han, C. Long, S. Hua, Y. Zhang, S. Ji, L. Xu, C. Zhou, D. Xu, A. Cherubini, L. Valenti, P. Gu, S. Zang, W. Jiang, Z. Huang
MASLD in Adults With Type 1 Diabetes and Type 2 Diabetes Undergoing Vibration-Controlled Transient Elastography
2026 A. Mantovani, E. Scoccia, R. Morandin, M. Lando, V. Fiorio, A. Taverna, I. Milani, M. Chinucci, M. Parrotta, L. Colangeli, S. Palleschi, P. Sbraccia, F. Leonetti, L. Valenti, D. Capoccia, G. Targher, V. Guglielmi
Once-monthly efimosfermin for non-cirrhotic MASH
2026 L. Valenti, G. Periti
Iron, autoimmunity, and thrombosis: Exploring sex-specific interactions
2026 R. Gualtierotti, L. Valenti
Sex Differences in Cancer-Associated Thrombosis
2026 A. Giachi, D. Santagata, A. Truma, A. Artoni, P. Bucciarelli, L. Valenti, C. Ay, R. Gualtierotti
Effectiveness of a Model of Care Based on Fibrosis-4 and Liver Stiffness Measurement for the Screening of Patients With Type 2 Diabetes Mellitus at Risk of Advanced Liver Disease: Results From an Italian Prospective Multicenter Study
2026 G. Caviglia, A. Ferro, R. D'Ambrosio, R. Perbellini, P. Lampertico, G. Periti, L. Valenti, C. Ciccioli, G. Pennisi, S. Petta, L. Brodosi, M. Petroni, F. Marchignoli, L. Pironi, A. Sagripanti, M. Argenziano, G. Svegliati-Baroni, C. Rosso, F. Barutta, A. Armandi, G. Gruden, E. Bugianesi
Prevalence, type, and clinical implications of CFTR variants in bronchiectasis
2026 A. Gramegna, L. Allavena, G. Alicandro, E. Canella, M. Nigro, C. Premuda, M. Ori, M. Santambrogio, L. Porcaro, D. Prati, L. Valenti, S. Aliberti, F. Blasi
Association of SARS-CoV-2 infection with long-lasting increase in circulating IL-32 levels
2026 L. Miano, E. Sinopoli, A. Cherubini, C. Suffritti, S. Pelusi, F. Rahmeh, G.E. Lamorte, F. Peyvandi, F. Blasi, G. Grasselli, A. Bandera, R. Gualtierotti, D. Prati, L.V.C. Valenti
Early BAL microRNA Signatures Delineate Biological Trajectories Towards CLAD After Lung Transplantation
2026 G. Gaudioso, S. Franzi, R. Orlandi, M.R.D. Filippo, A. Terrasi, A.M. Storaci, N. Mansour, B. Digiuni, D. Marchelli, L.V.C. Valenti, G.D. Turris, F. Von Herz, G. Garulli, M. Nosotti, L.C. Morlacchi, F. Blasi, A. Palleschi, V. Vaira
Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma
2026 M. Mureddu, S. Pelusi, O. Jamialahmadi, M. Vujkovic, L. Miano, H. Eidgah Torghabehei, L. Ronzoni, F. Malvestiti, M. Saracino, G. Periti, V. Moretti, C. Teerlink, J. Lynch, P. Tsao, J. Johnson, V. La Mura, R. Dilena, S. Alqahtani, A. Cherubini, F. Russo, R. D'Ambrosio, M. Fraquelli, S. Petta, L. Miele, U. Vespasiani-Gentilucci, E. Bugianesi, R. Mancina, P. Parini, D. Prati, K. Chang, C. Schneider, S. Romeo, L. Valenti
Metabolic dysfunction-associated steatotic liver disease
2025 G. Targher, L. Valenti, C. Byrne
Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways
2025 M. Vujkovic, D. Kaplan, J. Ghouse, B. Loza, J. Brancale, A. Lewis, D. Zhang, M. Levin, O. Veatch, J. Johnson, C. Schneider, A. Verma, K. Wangensteen, E. Scorletti, D. Gill, C. Konkwo, A. Garófalo, L. Guare, T. Schwantes-An, M. Abreu, H. Gellert-Kristensen, O. Pedersen, C. Erikstrup, J. Bundgaard, E. Sørensen, S. Ostrowski, H. Bundgaard, K. Lee, A. Shaked, K. Olthoff, M. Hoteit, E. Speliotes, Y. Chen, A. Oliveri, L. Yin, L. Valenti, F. Malvestiti, D. Marchelli, L. Miano, Q. Anstee, A. Daly, H. Cordell, R. Darlay, N. Verweij, G. Hindy, A. Locke, K. Matsuura, S. Asrani, G. Testa, L. Lotta, M. Jones, D. Dochtermann, T. Norden-Krichmar, C. Teerlink, P. Devineni, S. Pyarajan, D. Rader, Y. Tanaka, B. Voight, S. Vilarinho, L. Bastarache, S. Stender, P. Tsao, B. Penn Medicine, C. Dbds Genomic, B. Biovu, I. Michigan Genomics, C. Regeneron Genetics, B. Indiana, P. All Of Us Research, B. Milano, C. Litmus, P. Va Million Veteran, T. Morgan, J. Lynch, K. Chang
Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis
2025 A. Mangia, L. Valenti
Diagnostic Yield of Whole Exome Sequencing in Adult-onset Cholestatic Liver Disease
2025 M. Scaravaglio, L. Ronzoni, L. Cristoferi, L. Miano, E. Nofit, A. Gerussi, F. Malinverno, V. Moretti, V. Torcianti, C. Caime, M. Cadamuro, L. D'Antiga, P. Invernizzi, M. Carbone, L. Valenti
Response to Letter to the Editor: "Advancing TMPRSS6-Targeted Therapy for MASLD: Mechanistic and Translational Perspectives"
2025 M. Pettinato, A. Pagani, A. Nai, L. Valenti, L. Silvestri
Bringing genetic testing into the clinical management of people with MASLD: Are we there yet?
2025 L. Valenti, H. Hagström
Interplay among lipoprotein(a), hepatic and vascular damage in individuals with metabolic dysfunction
2025 S. Pelusi, C. Macchi, F. Malvestiti, S. Margarita, I. De Matteis, G. Periti, J. Rondena, S. Mira, F. Iemma, M. Tranchina, B. Nardi, C. Lucci, C. Sirtori, O. Millet, J. Mato, G. Targher, D. Prati, M. Ruscica, L. Valenti